ライフサイエンスコーパス: SLPI

1 SLPI also suppressed activation of the transcription fac

2 SLPI and PEPI form complexes, preventing elastase from c

3 SLPI and Smad2 may therefore represent new targets for t

4 SLPI appears to function as an endogenous regulator of l

5 SLPI binding shows little temperature dependence and a s

6 SLPI caused a decrease in the binding of LPS to sCD14 as

7 SLPI did not alter NF-kappaB activation in alveolar macr

8 SLPI directly inhibits elastase and other serine proteas

9 SLPI downregulation was associated with activation of NF

10 SLPI expression increased during resolving phase of the

11 SLPI is a pivotal mediator of anti-inflammatory response

12 SLPI is a secreted serine protease inhibitor, which is o

13 SLPI is expressed in MKs and platelets in 2 discrete com

14 SLPI levels in saliva and semen but not breast milk appr

15 SLPI may thus have unanticipated roles in MK and platele

16 SLPI mRNA was similar in whole lung and alveolar type II

17 SLPI production correlated with bactericidal activity wi

18 SLPI protein expression and antineutrophil elastase acti

19 SLPI protein is detectable in intestinal lavage fluids c

20 SLPI release is also stimulated by activation of protein

21 SLPI responsiveness to HIV-1 was also observed in an unr

22 SLPI selectively increased cyclin D1 gene expression, wi

23 SLPI transfectants and mock transfectants did not differ

24 SLPI was localized in neurons and astrocytes in the peri

25 SLPI(-/-) mice show intact proplatelet formation, platel

26 in vitro assay measuring invasive activity, SLPI blocked protease-dependent tumor cell migration.

27 emic lesion over controls at the site of Adv/SLPI expression (p < 0.01, n = 8) and significantly impr

28 ombinant adenovirus overexpressing SLPI (Adv/SLPI) into the cortical tissue resulted in up to 58.4% r

29 the presence and absence of antihuman (alpha)SLPI.

30 trations of RANTES (R2=0.68 and P<.0001) and SLPI (R2=0.29 and P=.001) correlated with BAL fluid HIV-

31 -70, nuclear CXCL-1, cytoplasmic CXCL-1, and SLPI, respectively).

32 In inflamed lung both TIMP-2 and SLPI appeared to exist as enzyme inhibitor complexes.

33 Lung expression of both TIMP-2 and SLPI appeared to involve endothelial and epithelial cell

34 The data suggest that endogenous TIMP-2 and SLPI dynamically regulate the intensity of lung inflamma

35 ch is a substrate of transglutaminasa-2) and SLPI (protein with anti-inflammatory, anti-bacterial and

36 t importantly, free cysteines of SLPI-6A and SLPI-7A also act as a thiol catalyst in promoting the di

37 Properties of SLPI-6A and SLPI-7A were investigated and compared to those of other

38 ncluding two nativelike isomers, SLPI-6A and SLPI-7A, as transient intermediates.

39 ptor 1* were stimulated with Mtb antigen and SLPI, and IFN-gammaR expression levels were measured.

40 ssion of two elastase inhibitors, elafin and SLPI, has been related to several hyperproliferative ski

41 from medical records, oral examination, and SLPI enzyme-linked immunosorbent assay quantitation of w

42 hil elastase was significantly increased and SLPI and elafin significantly reduced after rhinovirus i

43 OPD with secondary bacterial infections, and SLPI and elafin levels correlated inversely with bacteri

44 lpha and anti-microbial genes Lysozyme M and SLPI in the colon of Muc4(-/-) mice compared with WT lit

45 encing of the COL8A2, BFSP1, CST3, MMP9, and SLPI genes were performed in 14 unrelated, affected pati

46 tified in the COL8A2, BFSP1, CST3, MMP9, and SLPI genes, no presumed pathogenic sequence variants wer

47 rotein levels of UBE3C, Atrogin-1, MURF1 and SLPI were unchanged (P > 0.05).

48 ase, and IL-1beta and declines in NEAPCs and SLPI.

49 creased expression of SLPI messenger RNA and SLPI protein, which was found in hepatocytes.

50 Enforced expression of SERPINE2 and SLPI in human breast cancer cell lines also programmed t

51 them for vascular mimicry, and SERPINE2 and SLPI were overexpressed preferentially in human patients

52 In this study, WT SLPI and SLPI mutants with various degrees of protease-inhibitory

53 Anti-SLPI antibody significantly decreased bactericidal activ

54 nflammatory model used, the presence of anti-SLPI caused accentuated activation of NF-kappaB.

55 fected by treatment with anti-TIMP-2 or anti-SLPI.

56 Treatment of mice with anti-SLPI enhanced serum levels of TNF-alpha and MIP-2 and in

57 nd to be downregulated (antileukoproteinase [SLPI], 0.6-fold; WAP 4-disulfide core domain protein [WF

58 oncogenic pathway and a tumor suppressor, as SLPI-repressed gene, whose expression is up-regulated by

59 There was no association between SLPI concentration and HIV-1 transmission overall.

60 A direct association between SLPI levels and the severity of TB was detected.

61 Furthermore, an inverse correlation between SLPI and histological parameters associated with tumor p

62 noviral overexpression of Smad2 also blocked SLPI-induced axonal regeneration.

63 Both SLPI and IFN-gamma were significantly enhanced in plasma

64 lungs, inhibition of NF-kappaB activation by SLPI was associated with elevated levels of lung IkappaB

65 S from soluble CD14 (sCD14)-LPS complexes by SLPI-overexpressing cells was only 50% of that seen in c

66 ted cleavage products were all diminished by SLPI treatment in acute and chronic arthritis, indicatin

67 eraction with annexin II can be disrupted by SLPI or other annexin II-specific inhibitors.

68 strain of group A streptococci was killed by SLPI, and the antibacterial activity of this protein was

69 bnormal proliferation such as in carcinomas, SLPI may define a novel pathway by which cellular growth

70 Cellular SLPI levels negatively influenced the anti-proliferative

71 rate a positive correlation between cellular SLPI production and proliferation.

72 Depressed cervicovaginal SLPI levels have been correlated with both Trichomonas v

73 Matrix metalloproteinase (MMP)-12 cleaved SLPI and incubation with SP-A reduced MMP-12-mediated SL

74 In contrast, SLPI does not influence epithelial barrier integrity as

75 Significantly decreased SLPI was detected in OSCC compared to normal oral epithe

76 f oxidative folding of reduced and denatured SLPI has been investigated here.

77 immediate-early gene failed to downregulate SLPI or activate NF-kappaB.

78 ve generated mice null for the gene encoding SLPI (Slpi), which show impaired cutaneous wound healing

79 s of exogenously administered and endogenous SLPI on liver and lung injury induced by hepatic ischemi

80 flammatory erosive polyarthritis, endogenous SLPI was unexpectedly upregulated at both mRNA and prote

81 perfusion injury and suggest that endogenous SLPI functions to regulate the hepatic inflammatory resp

82 In vitro, SP-A enhanced SLPI production by macrophage THP-1 cells but not respir

83 istration of SP-A to SP-A(-/-) mice enhanced SLPI protein expression and antineutrophil elastase acti

84 sion in the presence or absence of exogenous SLPI or neutralizing antibodies to SLPI.

85 uman oral squamous cell carcinoma (OSCC) for SLPI expression in parallel with proteases associated wi

86 These data support a key role for SLPI in the oral mucosal defense against C. albicans.

87 In mice subjected to our SA model, forced SLPI expression decreased AHR in the absence of CS, and

88 SA characterized by a dysregulated IFN-gamma/SLPI axis that affects lung function.

89 We have generated SLPI-ablated epithelial sublines by stably transfecting

90 nds leading to the conversion of SLPI-6A --> SLPI-7A --> N-SLPI is relatively slow and represents the

91 However, SLPI is released upon platelet activation, which also re

92 ndometrial cell line with an antisense human SLPI RNA expression vector.

93 es the protease-reactive site found in human SLPI.

94 tion, to determine whether recombinant human SLPI blocks activation of isolated human neutrophils.

95 We show, in addition, that recombinant human SLPI can bind to purified endotoxin in vitro.

96 We found that recombinant human SLPI in vitro inhibits TNF-alpha-induced hydrogen peroxi

97 of LPS-challenge mice with recombinant human SLPI or Elafin accelerated resolution, an effect associa

98 ts known inhibition of elastase, we identify SLPI as a novel inhibitor of plasminogen activation thro

99 These findings implicate SLPI as a potential biomarker of resistance to AR inhibi

100 To determine whether or not changes in SLPI correlate with the severity of multiple organ dysfu

101 ng PEPI corrects the wound-healing defect in SLPI null mice.

102 neovascularization was much more extended in SLPI and Buffer animals than in animals treated with PF-

103 oes not occur after a conditioning lesion in SLPI null mutant mice, indicating that expression of SLP

104 WAP motifs are present in SLPI and elafin, two antiproteinases located on chromoso

105 red a significant and sustained reduction in SLPI levels.

106 NE or treatment with exogenous NE increased SLPI messenger RNA and protein levels, whereas transduct

107 o HIV-1 BaL and HXB2 significantly increased SLPI mRNA and protein production compared to that in moc

108 APCs) and secretory leukoprotease inhibitor (SLPI) significantly decreased over time.

109 IMP-2) and secreted leukoprotease inhibitor (SLPI) were cloned, expressed, and shown to be up-regulat

110 lation of secretory leukoprotease inhibitor (SLPI), an inhibitor of serine proteases, was assessed.

111 effect of secretory leukoprotease inhibitor (SLPI), and to investigate the antigen specificity of bot

112 peptides secretory leukoprotease inhibitor (SLPI), elafin, pentraxin, LL-37, alpha-defensins and bet

113 hat secretory leukocyte peptidase inhibitor (SLPI) is regulated by the AR in a ligand-independent man

114 n of secretory leukocyte protease inhibitor (SLPI) at entry portals indicates its involvement in defe

115 Secretory leukocyte protease inhibitor (SLPI) concentrations of apical washes from premenopausal

116 n of secretory leukocyte protease inhibitor (SLPI) during hepatic ischemia and reperfusion in mice.

117 Secretory leukocyte protease inhibitor (SLPI) has been proposed as a potential inhibitor of HIV-

118 n of secretory leukocyte protease inhibitor (SLPI) impacts on tumor progression.

119 l of secretory leukocyte protease inhibitor (SLPI) in erosive joint diseases, we cloned, sequenced, a

120 Secretory leukocyte protease inhibitor (SLPI) inhibits chymotrypsin, trypsin, elastase, and cath

121 Secretory leucocyte protease inhibitor (SLPI) is a 107-amino acid protein with a high density of

122 Secretory leukocyte protease inhibitor (SLPI) is a 12-kDa secreted protein initially identified

123 that secretory leukocyte protease inhibitor (SLPI) is a pattern recognition receptor with anti-mycoba

124 Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor with anti-microbial

125 The secretory leukocyte protease inhibitor (SLPI) is found in a variety of secreted fluids in mammal

126 Secretory leukocyte protease inhibitor (SLPI) is responsible for regulating inflammatory damage

127 n of secretory leukocyte protease inhibitor (SLPI) is strongly upregulated in response to elevation o

128 king secretory leukocyte protease inhibitor (SLPI) leads to impaired wound healing due to enhanced ac

129 Secretory leukocyte protease inhibitor (SLPI) modulates monocyte/macrophage function through inh

130 with secretory leukocyte protease inhibitor (SLPI) renders these cells refractory to LPS stimulation.

131 n of secretory leukocyte protease inhibitor (SLPI) suppressed acute lung injury induced by deposition

132 and secretory leukocyte protease inhibitor (SLPI) were not different when the subjects were compared

133 Secretory leukocyte protease inhibitor (SLPI), a 12-kDa antiprotease, suppresses the growth of C

134 that secretory leukocyte protease inhibitor (SLPI), a 12-kDa mucosal antiviral protein, is a componen

135 Secretory leukocyte protease inhibitor (SLPI), a protein found in saliva, breast milk, and genit

136 ated secretory leukocyte protease inhibitor (SLPI), a serine protease antagonist characterized princi

137 Secretory leukocyte protease inhibitor (SLPI), an anti-inflammatory mediator of mucosal immunity

138 t is secretory leukocyte protease inhibitor (SLPI), an approximately 12-kDa non-glycosylated protein

139 NE), secretory leukocyte protease inhibitor (SLPI), in myeloid cells and plasma of patients with seve

140 , and secreted leukocyte protease inhibitor (SLPI), were studied further with breast cancer tissue mi

141 a to secretory leukocyte protease inhibitor (SLPI), which is expressed by airway epithelial cells, an

142 1) and secretory leuko-proteinase inhibitor (SLPI) gene induction.

143 Secretory leukocyte proteinase inhibitor (SLPI) is a major serine proteinase inhibitor, a potent a

144 Secretory leukocyte proteinase inhibitor (SLPI) is a well-established inhibitor of serine protease

145 y, secretory leukocyte proteinase inhibitor (SLPI), lysozyme, and lactoferrin.

146 ral (secretory leukocyte protease inhibitor [SLPI]; Elafin) protease inhibitors on the resolution of

147 1A, MT1F, MT1H), and the protease inhibitor, SLPI (P < 0.05) at 2 days and 5 days post-SCI.

148 etallothioneins, and the protease inhibitor, SLPI, within 5 days of SCI.

149 e isomers, including two nativelike isomers, SLPI-6A and SLPI-7A, as transient intermediates.

150 6) and five repressed (CCR2, VpreB, lambda5, SLPI, and CMAP/Cystatin7) genes, respectively, were bona

151 those with an abnormal vaginal pH had lower SLPI levels as compared to their peers.

152 When instilled into normal lung, SLPI also caused similar changes (increases) in lung Ika

153 incubation with SP-A reduced MMP-12-mediated SLPI cleavage.

154 ow that Mtb-induced IFN-gamma down-modulated SLPI levels by signaling through the IFN-gammaR in HDs.

155 Moreover, SLPI exhibits an antibacterial activity against at least

156 the conversion of SLPI-6A --> SLPI-7A --> N-SLPI is relatively slow and represents the final stage o

157 plains why a near-quantitative recovery of N-SLPI can be achieved in the absence of any thiol catalys

158 ss, studies of reductive unfolding of native SLPI and oxidative folding of a six-disulfide variant of

159 d a near-quantitative recovery of the native SLPI can be achieved in a simple buffer solution using a

160 om pathogens, consistent with the ability of SLPI to inhibit human immunodeficiency virus (HIV)-1 inf

161 nic arthritis, indicating that the action of SLPI may extend beyond inhibition of serine proteases.

162 cal inhibitor of the antibacterial action of SLPI to be described and may prove to be an important to

163 Inhibition of the antibacterial actions of SLPI and lysozyme would be advantageous to S. pyogenes i

164 of SIC to block the biological activities of SLPI and lysozyme.

165 zymatic activity of NE or on the activity of SLPI cannot be implicated in the pathogenesis of CIMDL.

166 vity of NE and on the inhibitory activity of SLPI was investigated by determining the hydrolysis of N

167 d not inhibit the antiproteinase activity of SLPI, implying that there is specific inhibition of the

168 E and did not interfere with the activity of SLPI.

169 sis independent of anti-protease activity of SLPI.

170 were reversed by inhibiting the activity of SLPI.

171 The binding of SLPI with Cementoin to transglutaminase seems to be an e

172 Characterization of SLPI and other endogenous antiviral molecules may enhanc

173 Further, serum concentrations of SLPI (132+/-15 ng/mL) were elevated in septic surgical p

174 es demonstrate that higher concentrations of SLPI in mucosal secretions are associated with a reduced

175 Physiologic concentrations of SLPI potently protect adherent monocytes and activated p

176 Hepatic and circulatory concentrations of SLPI were elevated in AALF and immunohistochemistry reve

177 disulfide bonds leading to the conversion of SLPI-6A --> SLPI-7A --> N-SLPI is relatively slow and re

178 Most importantly, free cysteines of SLPI-6A and SLPI-7A also act as a thiol catalyst in prom

179 We further found that downregulation of SLPI in CD34(+) bone marrow (BM) hematopoietic progenito

180 SLPI levels revealed that downregulation of SLPI with short hairpin RNA (shRNA) upregulated nuclear

181 hibition of NE resulted in downregulation of SLPI.

182 data confirm the anti-inflammatory effect of SLPI in lung and point to a mechanism of anti-inflammato

183 we demonstrated that the oncogenic effect of SLPI may be due to protection of growth factor progranul

184 esults suggest that the inhibitory effect of SLPI on macrophage responses to LPS may, in part, be due

185 d the mechanism of the protective effects of SLPI in this model.

186 The in vivo suppressive effects of SLPI mutants on lung vascular permeability, neutrophil r

187 nsistent with the known inhibitor effects of SLPI on NF-kappaB pathways.

188 data suggest that the suppressive effects of SLPI on the intrapulmonary activation of NF-kappaB and n

189 a mechanism of anti-inflammatory effects of SLPI.

190 ounting for the unique folding efficiency of SLPI in the absence of a redox agent.

191 gamma was unable to modify the expression of SLPI in TB patients.

192 Because expression of SLPI is generally high in epithelial cells exhibiting ab

193 l mutant mice, indicating that expression of SLPI is required for the conditioning lesion effect.

194 d reperfusion caused increased expression of SLPI messenger RNA and SLPI protein, which was found in

195 gest that the ischemia-induced expression of SLPI might play a neuroprotective role in focal stroke,

196 the refolding process, oxidative folding of SLPI turns out to be surprisingly simple and efficient.

197 r studies indicate that oxidative folding of SLPI undergoes heterogeneous populations of one-, two-,

198 nt study, we described the identification of SLPI expression in ischemic cortex by suppression subtra

199 Intravenous infusion of SLPI reduced liver and lung damage and diminished neutro

200 tion of IFN-gamma reversed the inhibition of SLPI induced by Mtb antigen in HDs, but not in TB patien

201 ich was partially reversed with knockdown of SLPI.

202 Plasma levels of SLPI and IFN-gamma were studied in healthy donors (HDs)

203 We measured levels of SLPI in 215 vaginal specimens collected from adolescent

204 ed whether IFN-gamma modulated the levels of SLPI in TB patients.

205 Circulating levels of SLPI, monocyte cluster of differentiation 163 (CD163), h

206 et mount positive) would prevent the loss of SLPI and impaired vaginal immunity.

207 se PCR studies demonstrated that the loss of SLPI is mediated by downregulation of gene expression.

208 t the hypothesis that HSV triggers a loss of SLPI to evade innate immunity and that this response may

209 The correlation between the mechanism of SLPI folding and the three-dimensional structure of SLPI

210 ze with pDCs in psoriatic skin, a mixture of SLPI with neutrophil DNA and HNE induced a marked produc

211 hat SIC binds approximately two molecules of SLPI and four molecules of lysozyme.

212 However, the oncogenic potential of SLPI in prostate cancer remains unknown.

213 The presence of SLPI caused greatly reduced activation (ie, nuclear tran

214 The presence of SLPI in the IgG immune complex-model of lung injury redu

215 n polymerase chain reaction, the presence of SLPI messenger RNA in human model intestinal epithelial

216 In the presence of SLPI, content of tumor necrosis factor-alpha, CXC chemok

217 postmenopausal) influences the production of SLPI and bactericidal activity by uterine epithelial cel

218 ed constitutive expression and production of SLPI in immortalized human oral keratinocytes.

219 Properties of SLPI-6A and SLPI-7A were investigated and compared to th

220 -like region of SP-A conferred protection of SLPI against MMP mediated cleavage.

221 Reciprocal regulation of SLPI by NE is well documented, and we previously demonst

222 In this first report of SLPI regulation by HIV-1, we show that the expression an

223 of this study were to establish the role of SLPI in AALF.

224 sorbent assay, the constitutive secretion of SLPI occurs in a markedly polarized manner toward the ap

225 nt tissue determined the cellular sources of SLPI and hepatic macrophage phenotype.

226 HIV-1-mediated stimulation of SLPI occurred at the transcriptional level, was dose and

227 lding and the three-dimensional structure of SLPI is also elaborated.

228 ed and sequenced and is identical to that of SLPI isolated previously from the human parotid gland.

229 (200 ug/ml; n = 12), Group 2, with 10 ul of SLPI (200 ug/ml; n = 12) and Group 3 was treated with bu

230 dative folding of a six-disulfide variant of SLPI enable us to propose an underlying mechanism accoun

231 with polyclonal rabbit Abs to rat TIMP-2 or SLPI.

232 n of a recombinant adenovirus overexpressing SLPI (Adv/SLPI) into the cortical tissue resulted in up

233 that in lesional skin of psoriasis patients, SLPI together with its enzymatic target HNE and DNA, is

234 D and cleavage of the antimicrobial peptides SLPI and elafin by virus-induced neutrophil elastase may

235 es encoding specific antimicrobial peptides (SLPI and CAMP).

236 Protein levels of antimicrobial peptides (SLPI, HNP 1-3, elafin, and LL-37) and neutrophil chemoki

237 vation (50.2+/-4.0 ng/mL, p = .01) in plasma SLPI 12 hrs after administration of lipopolysaccharide t

238 Platelet SLPI inhibits neutrophil elastase, an activity that is r

239 ve a bactericidal effect, nor did it produce SLPI.

240 In contrast, HEC-1B cells produced SLPI and a factor that inhibited bacterial growth.

241 Although the ability of recombinant (r) SLPI to inhibit HIV-1 infection of macrophages and prima

242 cloned, sequenced, and expressed active rat SLPI, which shares the protease-reactive site found in h

243 Our full-length rat SLPI cDNA shares 81% and 63% amino acid sequence identit

244 ystemic delivery of purified recombinant rat SLPI inhibited joint inflammation and cartilage and bone

245 Recombinant SLPI attenuates digestive enzyme (trypsin)- or leukocyte

246 ed myeloid differentiation caused by reduced SLPI levels revealed that downregulation of SLPI with sh

247 ed in AALF and immunohistochemistry revealed SLPI expression in biliary epithelial cells and within h

248 ollowing culture with recombinant human (rh)-SLPI, liver homogenates, and plasma derived from AALF pa

249 By logistic regression modeling, a salivary SLPI level exceeding 2.1 microg/ml, low CD4 count, antir

250 ng the oral and systemic health and salivary SLPI levels in 91 dentate HIV-1-infected adults receivin

251 HIV-1 uninfected at 1 month, higher salivary SLPI levels were associated with a decreased risk of HIV

252 oup had a significantly higher mean salivary SLPI level than the comparison group (1.9 microg/ml vers

253 Infants' median salivary SLPI concentrations were higher at birth than at 6 month

254 al candidiasis as key predictors of salivary SLPI and revealed a significant interaction (P < 0.05) b

255 haryngeal candidiasis in predicting salivary SLPI level.

256 l epithelium expresses and apically secretes SLPI, a molecule that may significantly contribute to th

257 ely linked genes (WFDC12, PI3, SEMG1, SEMG2, SLPI, and MATN4) that show strong patterns of adaptive s

258 Serum SLPI concentrations correlated (r2 = .71, p < .01) bette

259 Serum SLPI is elevated in human sepsis and experimental endoto

260 In addition, serum SLPI levels are significantly elevated in metastatic CRP

261 To compare changes in serum SLPI in human sepsis with changes in interleukin (IL)-6,

262 Maximal concentrations of serum SLPI correlate significantly with maximal multiple organ

263 ther sexually transmitted infections (STIs), SLPI levels were lower in females with a positive T. vag

264 We conclude that SLPI localizes in part along the MK and platelet MT cyto

265 Northern blot analysis confirmed that SLPI mRNA was significantly induced in the ischemic brai

266 We now demonstrate that SLPI binds to the membrane of human macrophages through

267 Mechanistically, we demonstrate that SLPI localizes to the nuclei of neurons, binds to the Sm

268 We demonstrated that SLPI expression has functional significance, as it promo

269 Here we provide the first evidence that SLPI is upregulated in a subset of CRPC cell lines and C

270 al infection, leading to the hypothesis that SLPI may have a role in this process.

271 Taken together, these results indicate that SLPI controls the proliferation, differentiation, and ce

272 These data indicate that SLPI has protective effects against hepatic ischemia/rep

273 These findings indicate that SLPI is a component of the oral mucosal response to HIV-

274 We propose that SLPI is a pivotal endogenous factor necessary for optima

275 In this paper, we report that SLPI plays a previously uncharacterized role in regulati

276 We also show that SLPI can overcome inhibition by CNS myelin and significa

277 Our results suggest that SLPI acts at the node(s) of at least three major interac

278 Our data suggest that SLPI may possess antitumorigenic activity by virtue of i

279 These results suggest that SLPI plays an important role in reducing HIV-1 transmiss

280 The SLPI level could be used as a vaginal-health marker to e

281 The SLPI level was reduced by >50% in a T. vaginalis load-de

282 The SLPI mutant with Gly(72) (replacing Leu(72) ) lost its a

283 ition, Mtb antigen stimulation decreased the SLPI produced by peripheral blood mononuclear cells from

284 Thus, SLPI may contribute to psoriasis by enabling pDCs to sen

285 Thus, SLPI/elastase act via PEPI/EPIs to operate a switch at t

286 bers and shape, and marginal MT bands; thus, SLPI is not essential for thrombopoiesis.

287 exogenous SLPI or neutralizing antibodies to SLPI.

288 mmunosorbent assays showed that SIC binds to SLPI and to both human and hen egg lysozyme (HEL) but no

289 y lower in PF-MC treated animals compared to SLPI and buffer-treated animals at 18 hours and 24 hours

290 Log-transformed SLPI values were compared by analysis of variance or by

291 kawa sublines expressing low to undetectable SLPI have correspondingly increased and decreased expres

292 sence of CS, and it was further reduced when SLPI was combined with CS.

293 Whereas SLPI(+) neutrophils and NETs were found to colocalize wi

294 e aim of this study was to determine whether SLPI in infant saliva provides protection against mother

295 ion of the cell-surface molecule(s) to which SLPI binds rather than to changes in the rSLPI molecule.

296 lls, and IFN-gamma inversely correlated with SLPI expression in SA patients and the mouse model.

297 signaling, in myeloid cells transduced with SLPI shRNA.

298 In this study, WT SLPI and SLPI mutants with various degrees of protease-i

299 Gly(20) mutants were as effective as the WT SLPI in suppressing NF-kappaB activation and neutrophil

300 Wild-type (WT) SLPI has recently been shown to block nuclear factor kap